Efficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection.
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Pioglitazone (Primary)
- Indications Chronic granulomatous disease
- Focus Therapeutic Use
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.
- 07 May 2017 Planned End Date changed from 31 Dec 2019 to 31 Aug 2020.
- 07 May 2017 Planned primary completion date changed from 31 Dec 2019 to 31 Aug 2020.